Sign in to download the Issue in PDF format.
1Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, and Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Greece
2Haematology Department, Athens Medical Centre, Athens, Greece
O Katsouli
, VG Lainis, GG Kapellos, PG Vlachoyiannopoulos
We report a case of a 52-year-old female with Large Vessel Vasculitis (LVV) after vaccination with Oxford-AstraZeneca COVID-19 vaccine. She was presented with fever, started two weeks after the second dose of vaccine. Laboratory values, revealed elevated inflammatory markers and chronic disease anaemia. All the infectious causes were excluded, and immunology tests were negative. Computed Tomography (CT) demonstrated concentric wall thickening of ascending and descending aorta. Positron Emission Tomography (PET) scan showed increased vascular fluorodeoxyglucose (FDG), compatible with LVV. Within one month of treatment with high dose glucocorticoids and iv cyclophosphamide, laboratory findings normalised, and fever resolved.
Cite this article as: Katsouli OK, Lainis VG, Kapellos GG, Vlachoyiannopoulos PG. Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine. Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine. Mediterr J Rheumatol 2023;34(1):97-100.
Article Submitted: 20 Dec 2022; Revised Form: 30 Jan 2023; Article Accepted: 05 Feb 2023; Available Online: 31 Mar 2023
https://doi.org/10.31138/mjr.34.1.97
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2023 The Author(s).
